Literature DB >> 15554242

The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance.

Ulrich Hoffmann1, Heyo K Kroemer.   

Abstract

ATP-binding cassette (ABC) transporters comprise one of the largest membrane bound protein families. They are involved in transport of numerous compounds. These proteins transport substrates against a concentration gradient with ATP hydrolysis as a driving force across the membrane. Mammalian ABC proteins have important physiological, pharmacological and toxicological functions including the transport of lipids, bile salts, drugs, toxic and environmental agents. The efflux pumps serve both as natural defense mechanisms and influence the bioavailability and disposition of drugs. In general terms, the transporters remove xenobiotics from the cellular environment. For example, in cancer cells, over expression of these molecules may confer to multidrug resistance against cytostatic drugs. In addition, based on diverse structural characteristics and a broad substrate specifity, ABC transport proteins alter the intracellular concentration of a variety of therapeutically used compounds and toxicologically relevant agents. We review the function of the human multidrug resistance protein MDR1, (P-glycoprotein, ABCB1) and the multidrug resistance protein MRP2 (ABCC2). We focus on four topics namely 1) structure and physiological functions of these transporters, 2) substrates e.g., drugs, xenotoxins, and environmental toxicants including their conjugates, 3) drug-drug interactions, and the role of chemosensitizers which may be able to reverse drug resistance, and 4) pharmacologically and toxicologically relevant genetic polymorphisms in transport proteins and their clinical implications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554242     DOI: 10.1081/dmr-200033473

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  23 in total

Review 1.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

2.  Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.

Authors:  Brandon Swift; Xianbin Tian; Kim L R Brouwer
Journal:  Pharm Res       Date:  2009-06-04       Impact factor: 4.200

Review 3.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

4.  Equivalence-by-design: targeting in vivo drug delivery profile.

Authors:  Mei-Ling Chen; Vincent H L Lee
Journal:  Pharm Res       Date:  2008-10-28       Impact factor: 4.200

5.  Myocardial ischaemia inhibits mitochondrial metabolism of 4-hydroxy-trans-2-nonenal.

Authors:  Bradford G Hill; Sunday O Awe; Elena Vladykovskaya; Yonis Ahmed; Si-Qi Liu; Aruni Bhatnagar; Sanjay Srivastava
Journal:  Biochem J       Date:  2009-01-15       Impact factor: 3.857

6.  Generation of Scalable Hepatic Micro-Tissues as a Platform for Toxicological Studies.

Authors:  Sara Darakhshan; Ali Bidmeshki Pour; Reza Kowsari-Esfahan; Massoud Vosough; Leila Montazeri; Mohammad Hossein Ghanian; Hossein Baharvand; Abbas Piryaei
Journal:  Tissue Eng Regen Med       Date:  2020-07-14       Impact factor: 4.169

7.  Characterization of the ATPase activity of human ATP-binding cassette transporter-2 (ABCA2).

Authors:  Vladimir Beljanski; Athena Soulika; Jody M Tucker; Danyelle M Townsend; Warren Davis; Kenneth D Tew
Journal:  In Vivo       Date:  2005 Jul-Aug       Impact factor: 2.155

8.  Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing.

Authors:  Iñigo Narvaiza; Oscar Aparicio; María Vera; Nerea Razquin; Sergia Bortolanza; Jesús Prieto; Puri Fortes
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

9.  Multiple Drug Transporters Are Involved in Renal Secretion of Entecavir.

Authors:  Xi Yang; Zhiyuan Ma; Sisi Zhou; Yayun Weng; Hongmei Lei; Su Zeng; Liping Li; Huidi Jiang
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

10.  Metallothionein blocks oxidative DNA damage in vitro.

Authors:  Wei Qu; Jingbo Pi; Michael P Waalkes
Journal:  Arch Toxicol       Date:  2012-08-23       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.